

July 2, 2010

To those concerned

R-Tech Ueno, Ltd.
(Code No.4573, Osaka Securities Exchange; Hercules)
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
Representative: Yukihiro Mashima, Representative Director & President
Contact: Koji Nakamura, Business Management Department
TEL: 03-(3596) 8011

Announcement of Termination of Licensing Agreement for Rescula® Eye Drops
with Novartis Pharma

R-Tech Ueno, Ltd. and Novartis Pharma AG agreed to terminate the License Agreement for Rescula® Eye Drops (generic name: isopropyl unoprostone) under which R-Tech Ueno had granted Novartis Pharma AG the rights for the development and commercialization of Rescula® Eye Drops in overseas markets (except Taiwan, Korea, and North America).

R-Tech Ueno believes that the termination of the above agreement will not have a significant effect on results of operations.

• About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of marketing and R&D of drugs. Under leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and selling and developing pharmaceutical products through the eyes of doctors.” We are promoting development of new drugs of unmet medical needs (medical needs that are not fulfilled yet) which the government recommends and assists, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).